Literature DB >> 18063907

Epigenetic aberrations in malignant gliomas: an open door leading to better understanding and treatment.

Ramon Martinez1, Gabriele Schackert.   

Abstract

Malignant gliomas and specially glioblastoma multiforme are the most frequent and devastating brain tumors in adults. Intensive molecular and cytogenetical studies have revealed a wide variety of deregulated genes implicated in cell cycles, DNA repair, apoptosis, cell migration, invasion and angiogenesis with little translational success. An increasing number of reports investigating epigenetic injuries in malignant gliomas have been recently published, although the panorama of CpG island aberrant hypermethylation, histone modification and chromatin states in these lethal tumors is only partially devised. In the present analysis, we discuss the magnitude and significance of epigenetic lesions in the pathogenesis and mechanisms of progression of malignant gliomas as well as their influence on patient survival. The new venue of epigenetic research provides tools for the identification of genes differentially methylated that may be implicated in tumorigenesis and furthermore, epigenetics-based drugs may constitute a promising alternative resource of therapy for this, to the moment, incurable malignancy.

Entities:  

Mesh:

Year:  2007        PMID: 18063907     DOI: 10.4161/epi.2.3.5049

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  7 in total

1.  Inhibitory activities of trichostatin a in U87 glioblastoma cells and tumorsphere-derived cells.

Authors:  Felipe de Almeida Sassi; Lílian Caesar; Mariane Jaeger; Carolina Nör; Ana Lucia Abujamra; Gilberto Schwartsmann; Caroline Brunetto de Farias; Algemir Lunardi Brunetto; Patrícia Luciana da Costa Lopez; Rafael Roesler
Journal:  J Mol Neurosci       Date:  2014-01-25       Impact factor: 3.444

Review 2.  The evolution and application of techniques in molecular biology to human brain tumors: a 25 year perspective.

Authors:  James T Rutka; Paul Kongkham; Paul Northcott; Carlos Carlotti; Mustafa Guduk; Hirokatsu Osawa; Orlando Moreno; Ho Jun Seol; Andres Restrepo; Adrienne Weeks; Shoichi Nagai; Christian Smith
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

3.  DNA methylation in glioblastoma: impact on gene expression and clinical outcome.

Authors:  Amandine Etcheverry; Marc Aubry; Marie de Tayrac; Elodie Vauleon; Rachel Boniface; Frederique Guenot; Stephan Saikali; Abderrahmane Hamlat; Laurent Riffaud; Philippe Menei; Veronique Quillien; Jean Mosser
Journal:  BMC Genomics       Date:  2010-12-14       Impact factor: 3.969

4.  Gene expression mapping of histone deacetylases and co-factors, and correlation with survival time and 1H-HRMAS metabolomic profile in human gliomas.

Authors:  Nassim Dali-Youcef; Sébastien Froelich; François-Marie Moussallieh; Salvatore Chibbaro; Georges Noël; Izzie J Namer; Sami Heikkinen; Johan Auwerx
Journal:  Sci Rep       Date:  2015-03-20       Impact factor: 4.379

5.  Impact of somatic copy number alterations on the glioblastoma miRNome: miR-4484 is a genomically deleted tumour suppressor.

Authors:  Zahid Nawaz; Vikas Patil; Sivaarumugam Thinagararjan; Soumya A Rao; Alangar S Hegde; Arimappamagan Arivazhagan; Vani Santosh; Kumaravel Somasundaram
Journal:  Mol Oncol       Date:  2017-05-24       Impact factor: 6.603

6.  Molecular epigenetics, chromatin, and NeuroAIDS/HIV: translational implications.

Authors:  Paul Shapshak; Francesco Chiappelli; Deborah Commins; Elyse Singer; Andrew J Levine; Charurut Somboonwit; Alireza Minagar; Andras J Pellionisz
Journal:  Bioinformation       Date:  2008-10-07

7.  Altered expression of polycomb group genes in glioblastoma multiforme.

Authors:  Gang Li; Charles Warden; Zhaoxia Zou; Josh Neman; Joseph S Krueger; Alisha Jain; Rahul Jandial; Mike Chen
Journal:  PLoS One       Date:  2013-11-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.